Hepa Thera Honored with "VBEF Medical and Health Industry Innovation Product List Top 100"

On May 9, 2024, at the "2024 Future Health 100 Strong Selection" held in Beijing, Hepa Thera was honored with the "VBEF Medical and Health Industry Innovation Product List Top 100". 

The Future Health 100 Strong list, launched by VB100, Artery Network, and Eggshell Research Institute, is the first domestic list targeting non-listed enterprises in the innovative medical field. It aims to select Chinese innovative medical practitioners who truly represent the future of healthcare, discover the core strength of China's future medical industry, and promote the innovative transformation process of the health industry. 

Hepa Thera's hepatitis B siRNA drug HT-101, as the first domestically approved siRNA hepatitis B treatment product to enter clinical trials, has shown excellent clinical data, demonstrating a significant reduction in the level of hepatitis B surface antigen. This achievement not only showcases Hepa Thera's R&D strength in the field of biopharmaceuticals but also indicates that HT-101 has the potential to become a cornerstone product for the cure of hepatitis B. 

Hepa Thera's selection for the "VBEF Medical and Health Industry Innovation Product List Top 100" highlights the company's innovation in the field of liver diseases and fully demonstrates Hepa Thera's firm determination and unremitting efforts in the research and development of innovative drugs for liver diseases.